JAZZ
Jazz Pharmaceuticals is a biopharmaceutical company developing life-changing medicines for rare diseases across epilepsies, cancers, and sleep disorders using small molecule and biologic modalities. The company markets several approved products including Xywav (sodium oxybate oral solution) for narcolepsy, Epidiolex (cannabidiol oral solution) for seizure disorders, the bispecific antibody Ziihera (zanidatamab-hrii) for HER2-positive biliary tract cancer, Modeyso (dordaviprone) for diffuse midline glioma, Zepzelca (lurbinectedin) for small cell lung cancer, and Rylaze (asparaginase erwinia chrysanthemi recombinant) for acute lymphoblastic leukemia, with an ongoing pipeline of early-, mid-, and late-stage rare disease programs.
Pipeline
Pyrimidine analog chemotherapy that inhibits thymidylate synthase, blocking DNA synthesis. Foundational in colorectal, breast, and head/neck cancers (FOLFOX, FOLFIRI regimens).
Oral 5-fluorouracil prodrug activated to 5-FU in tumor tissue. Used in colorectal, breast, and gastric cancers, often combined with oxaliplatin or platinum.
Platinum-based chemotherapy that forms DNA crosslinks. Foundational cytotoxic agent used across testicular, bladder, ovarian, head and neck, and lung cancers.
Anti-PD-L1 monoclonal antibody (Imfinzi) that blocks PD-L1, restoring T-cell anti-tumor activity. Approved in NSCLC, SCLC, biliary tract cancer, and hepatocellular carcinoma.
Eribulin inhibits the growth phase of microtubules without affecting the shortening phase and sequesters tubulin into nonproductive aggregates.
Pyrimidine nucleoside analog chemotherapy that incorporates into DNA and inhibits ribonucleotide reductase. First-line in pancreatic cancer; used in lung, breast, and bladder cancers.
Third-generation platinum chemotherapy that forms DNA adducts. Backbone in colorectal cancer (FOLFOX) and other GI malignancies.
Anti-PD-1 monoclonal antibody (Keytruda) that blocks the PD-1 checkpoint, restoring anti-tumor immune response. FDA-approved across many cancers including NSCLC, melanoma, and gastroesophageal cancer.
Anti-PD-1 monoclonal antibody (Tevimbra) engineered to minimize FcγR binding. Approved in esophageal squamous cell carcinoma, NSCLC, and other cancers.
Anti-HER2 monoclonal antibody (Herceptin) that binds the extracellular domain of HER2, blocking signaling and triggering ADCC. Standard of care in HER2-positive breast and gastric cancers.
Vinorelbine is a vinca alkaloid that interferes with microtubule assembly. The antitumor activity of vinorelbine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin.
Biparatopic anti-HER2 bispecific antibody (Ziihera) that binds two distinct HER2 epitopes simultaneously, enhancing receptor clustering and signal disruption. Approved in HER2-positive biliary tract cancer.
Platinum-based chemotherapy that forms DNA crosslinks, inducing apoptosis in cancer cells. Standard of care across many solid tumors including NSCLC, ovarian, breast, bladder, and biliary cancers.
Taxane chemotherapy that stabilizes microtubules and arrests mitosis. Used in breast, prostate, NSCLC, head and neck, and gastric cancers.
Lurbinectedin is an alkylating drug that binds guanine residues in the minor groove of DNA, forming adducts and resulting in a bending of the DNA helix towards the major groove.
Taxane chemotherapy that binds β-tubulin and prevents microtubule depolymerization, causing mitotic arrest. Used in breast, ovarian, lung, and other cancers.
Pertuzumab targets the extracellular dimerization domain (Subdomain II) of the human epidermal growth factor receptor 2 protein (HER2) and, thereby, blocks ligand-dependent heterodimerization of HER2 with other HER family members, including EGFR, HER3, and HER4.
Catalyst Calendar
“Jazz Pharmaceuticals plc issued a press release announcing positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera® (zanidatamab-hrii) in combination with chemotherapy, and with or without the checkpoint inhibitor tislelizumab, as a first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma”